Ongoing research into Symprove - Inflammatory Bowel Disease
Listed Under: Symprove News
On going research into further medical benefits of Symprove
As well as organising independent trials to prove the benefits of Symprove for patients with Irritable Bowel Syndrome (IBS) Symprove have also commissioned further research to find out whether Symprove can benefit patients with Inflammatory Bowel Disease.
Inflammatory Bowel Disease
Assessment of Symprove as a dietary supplement in patients with inflammatory bowel disease who are in 'clinical' remission.
The investigator led study by NHS King's College Hospital, is now partially recruited with patients who have IBD (both ulcerative colitis or Crohn's). Results are due in shortly.
Please contact King's College Hospital, London, for patient referral.
Trial Registration: ISRCTN31320381
This trial has not closed.
Regular use of this multistrain probiotic may have anti-inflammatory properties and help improve the residual symptoms of inflammatory bowel disease (IBD) experienced by patients in 'clinical remission'.
160 patients with mild/moderate IBD will be randomly assigned (1:1 UC and 1:1 Crohn's disease) to receive 1 ml/kg/day (max 100 ml) of probiotic or placebo for 4 weeks.
Buy Symprove at Simply Sunshine